Home > Insider Trading > Filing (0001209191-21-044630)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1478320	Adaptive Biotechnologies Corp	ADPT	Biological Products, (No Disgnostic Substances) (2836)	270907024

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1799081	L Stacy Taylor	C/O Adaptive Biotechnologies 1551 Eastlake Ave E Ste 200 Seattle WA 98102	Svp And General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-06-30	1,042	$7.80	16,078	No	4	M	Direct
Common Stock	Acquisiton	2021-06-30	1,771	$6.55	17,849	No	4	M	Direct
Common Stock	Acquisiton	2021-06-30	1,354	$31.71	19,203	No	4	M	Direct
Common Stock	Disposition	2021-06-30	3,772	$41.35	15,431	No	4	S	Direct
Common Stock	Disposition	2021-06-30	395	$42.13	15,036	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-06-30	1,042	$0.00	1,042	$7.80
Common Stock	Stock Option (Right to Buy)	Disposition	2021-06-30	1,771	$0.00	1,771	$6.55
Common Stock	Stock Option (Right to Buy)	Disposition	2021-06-30	1,354	$0.00	1,354	$31.71

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
22,917	2029-04-23	No	4	M	Direct
15,938	2028-04-24	No	4	M	Direct
43,334	2030-02-13	No	4	M	Direct

Footnotes

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.00 to 41.58, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
The options vested with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.